On Air Now

Now Playing

Our Playlist »

Listen

Listen Live Now » 101.1 FM Green Bay, WI

Weather

Current Conditions(Green Bay,WI 54303)

More Weather »
62° Feels Like: 62°
Wind: NW 5 mph Past 24 hrs - Precip: 0.09”
Current Radar for Zip

Tonight

Partly Cloudy 57°

Tomorrow

Partly Cloudy 76°

Thurs Night

Partly Cloudy 59°

Alerts

EU agency rejects Sanofi, Isis cholesterol drug

LONDON (Reuters) - European regulators recommended against approval of Sanofi and Isis Pharmaceutical's Kynamro drug for treatment of a rare genetic disorder that causes unusually high cholesterol.

The European Medicines Agency said it was concerned about the medicine's safety, noting that a high proportion of patients stopped taking it within two years, mainly due to side effects such as flu-like symptoms, injection site reactions and liver toxicity.

The European rebuff contrasts with a green light for the drug, known generically as mipomersen, by a U.S. advisory panel in October.

Sanofi's Genzyme unit said it was disappointed by the decision and planned to request a re-examination.

A Sanofi spokeswoman said the company expected feedback from the regulator in the second quarter of 2013.

Isis founder and Chief Executive Stanley Crooke said on a conference call with analysts he was still optimistic on securing approvals in both the United States and Europe.

"Even though I cannot address the specific concerns of the (EU) committee ... I can say that each issue raised by the (committee) was thoroughly reviewed by the FDA," Crooke said. "We do not believe that today's opinion should have a negative impact elsewhere."

At 1514 GMT Sanofi shares were trading 0.1 percent lower at 71.72 euros, in line with the CAC 40 index, while Isis was up 0.3 percent at $9.87 in New York.

California-based Isis is entitled to 30 percent of total sales of Kynamro once the drug reaches the market, rising to 50 percent for sales over $2 billion.

(Reporting by Ben Hirschler; Additional reporting by Elena Berton in Paris and Zeba Siddiqui in Bangalore; Editing by David Cowell and David Holmes)

Comments